Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pandemics
NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
April 29th, 2009
NexBio, Inc. announced that it has completed the formation of a new Clinical Advisory Board (CAB) to complement its existing group of Senior Advisers. NexBio recently completed a First-In-Man clinical trial of DAS181 (Fludase(R)), an investigational drug candidate for influenza. The new CAB will guide NexBio throughout the clinical development of this novel medicine, helping the company to conduct advanced product development to address the threat of a potential influenza pandemic. The CAB is chaired by Andrew Pavia, M.D., who is joined by Robert Belshe, M.D., Kathryn Edwards, M.D., Allison McGeer, M.D., FRCPC, and Richard Whitley, M.D. "These individuals are among the...
Source: Vaccine Weekly (2009-04-29)
|
